Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-28. (canceled)

Claim 29. (new) A potassium salt of losartan in crystal Form X characterized by a powder X-ray diffraction pattern with peaks at about 6.9, 13.8, 20.6, 24.0, 24.8, 28.7 and 29.2 ± 0.2.

Claim 30. (new) A potassium salt of losartan in crystal Form Y characterized by a powder X-ray diffraction pattern with peaks at about 6.7, 13.8, 17.4, 19.2, 24.5, 24.8, 25.2 and 28.9 ± 0.2 degrees 2 Θ.

Claim 31. (new) A potassium salt of losartan in crystal Form X according to claim 29 characterized by a powder X-ray diffraction pattern essentially as depicted in Figure 31.

Claim 32. (new) A potassium salt of losartan in crystal Form Y according to claim 30 characterized by a powder X-ray diffraction pattern essentially as depicted in Figure 33.

Claim 33. (new) A potassium salt of losartan in crystal Form X according to Claim 29 which is characterized by a purity of at least about 99% by weight.

Claim 34. (new) A potassium salt of losartan in crystal Form X according to Claim 29 which is characterized by a purity of at least about 99.80% by weight.

Claim 35. (new) A potassium salt of losartan in crystal Form X characterized by a powder X-ray diffraction pattern with peaks at about 6.9, 13.8, 20.6, 24.0, 24.8, 28.7 and 29.2± 0.2 degrees 2 Θ, wherein said potassium salt of losartan is in the form of particles and wherein at least about 50% of said particles have a diameter of about 5 μm to about 500 μm.

Claim 36. (new) A potassium salt of losartan in crystal Form X according to Claim 29 wherein at least about 50% of particles have a diameter less than about 100 μm.

Claim 37. (new) A pharmaceutical composition comprising the potassium salt of losartan in crystal Form X according to Claim 29 and a pharmaceutically acceptable excipient.

Claim 38. (new) A pharmaceutical composition comprising the potassium salt of losartan in crystal Form Y according to Claim 30 and a pharmaceutically acceptable excipient.

Claim 39. (new) A method for treating hypertension in a patient in need of such treating comprising administering to said patient a therapeutically effective amount of the potassium salt of losartan in crystal Form X according to Claim 29.

Claim 40. (new) A method for treating hypertension in a patient in need of such treating comprising administering to said patient a therapeutically effective amount of the potassium salt of losartan in crystal Form Y according to Claim 30.

Claim 41. (new) A pharmaceutical composition in the form of a tablet comprising about 50mg of the potassium salt of losartan in crystal Form X according to Claim 29.

Claim 42. (new) A pharmaceutical composition in the form of a tablet comprising about 100mg of the potassium salt of losartan in crystal Form X according to Claim 29.

Claim 43. (new) A pharmaceutical composition in the form of a tablet comprising from about 50mg of the potassium salt of losartan in crystal Form X according to Claim 29 and about 12.50mg of hydrochlorothiazide.

Claim 44. (new) A crystalline sodium salt of losartain characterized by a powder X-ray diffraction pattern as depicted in Figure 21.

Claim 45. (new) A crystalline sodium salt of losartain having a purity of at least about 99.4% by weight and characterized by absorption peaks in the infrared spectrum of 1474, 1342, and 839 ± 5 cm^{-1}.

Claim 46. (new) A crystalline sodium salt of losartain having the infrared spectrum essentially as depicted in Figures 11 and 12.

Claim 47. (new) A crystalline calcium salt of losartain having a powder X-ray diffraction pattern essentially as depicted in Figure 24.

Claim 48. (new) A crystalline calcium salt of losartain having the infrared spectrum essentially as depicted in Figure 16.

Claim 49. (new) A crystalline calcium salt of losartain having a DSC thermogram essentially as depicted in Figure 6.

Claim 50. (new) A crystalline sodium salt of losartain having a DSC thermogram essentially as depicted in Figure 3.